Heart drug colchicine may reveal new clues to fight inflammation
NCT ID NCT07462325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a low dose of colchicine, an anti-inflammatory drug, changes proteins in the blood of people with coronary heart disease and high inflammation. Researchers will compare protein levels before and after one month of treatment in 176 patients. The goal is to find new biomarkers and targets for future therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine
What this could lead to
If successful, this study could identify new protein targets for treating inflammation in heart disease, potentially leading to better therapies.
What could go wrong
This is an early exploratory study focused on protein changes, not on clinical outcomes. The results may not translate into effective treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.